Secondcell Bio

SECONDCELL BIO Secondcell is about scaling up a validated platform biotechnology with multiple opportunities for carve-off IPO’s & licensing realizing ROI for investors. The company’s Chromovert® Technology originates from a Nobel-Prize winning laboratory at The Rockefeller University. Chromovert® is past start-up and ready to scale. $100M+ USD was invested to incubate the tech which is fully privately owned and unencumbered (no VC or U.S. gov’t funds used). Applications include drug discovery, personalized medicine, biologics manufacturing, cell and stem cell therapies, AgriTech including crop engineering and pest control, and more. We are currently exploring using the technology to create a new biotechnology hub in the UAE. With capital and leadership of the UAE to open new sectors, proprietary disruptive technologies like Chromovert® have the potential to leapfrog global competition and anchor the world’s next best biotechnology hub. CHROMOVERT® TECHNOLOGY Chromovert® is a disruptive cellular engineering biotechnology. Biological science deals with the human cell. Cells that exactly mimic human disease are fundamental for discovery of new drugs. However, in a sea of cells engineered to model disease, only a tiny number are suitable. Chromovert® permits the rapid purification of even rare, optimally engineered cells. Prior validation examples of the multi-use discovery engine include: 1) a novel nonaddictive painkiller discovered using Chromovert® and fast-tracked by the FDA was the subject IPO filing with the U.S. SEC. 2) Chromovert® was also used in strategic natural flavors research with The Coca-Cola Company, Kraft Foods and Nestle resulting in new natural sweeteners and the first-known salty-taste enhancers to cut salt and sugar in the diet.